Collections in this community

Recent Submissions

  • Thumbnail

    A beta oligomers promote oligodendrocyte differentiation and maturation via integrin beta 1 and Fyn kinase signaling 

    Quintela López, Tania; Ortiz Sanz, Carolina; Serrano Regal, María Paz; Gaminde Blasco, Adhara Mikaela; Valero Gómez-Lobo, Jorge; Baleriola, Jimena; Sánchez Gómez, María Victoria; Matute Almau, Carlos José; Alberdi Alfonso, Elena María (Nature Publishing Group, 2019-06-06)
    Alzheimer's disease (AD) is characterized by a progressive cognitive decline that correlates with the levels of amyloid beta-peptide (A beta) oligomers. Strong evidences connect changes of oligodendrocyte function with the ...
  • Thumbnail

    The Link of Inflammation and Neurodegeneration in Progressive Multiple Sclerosis 

    Pérez Cerdá, Fernando; Sánchez Gómez, María Victoria; Matute Almau, Carlos José (Biomed Central, 2016-05-24)
    Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage of the disease ...
  • Thumbnail

    Inflammation in stroke: the role of cholinergic, purinergic and glutamatergic signaling 

    Martín Muñoz, Abraham; Domercq García, María; Matute Almau, Carlos José (2018-05-04)
    The inflammatory response is a major factor in stroke pathophysiology and contributes to secondary neuronal damage in both acute and chronic stages of the ischemic injury. Recent work in experimental cerebral ischemia has ...
  • Thumbnail

    Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury 

    Cipriani, Raffaela; Chara Ventura, Juan Carlos; Rodríguez-Antigüedad Zarranz, Alfredo; Matute Almau, Carlos José (Biomed Central, 2017-07-24)
    Background: FTY720 (fingolimod, Gilenya (TM)) is an oral, blood-brain barrier (BBB)-passing drug approved as immunomodulatory treatment for relapsing-remitting form of the multiple sclerosis (MS). In addition, FTY720 exerts ...

View more